drugset / Trial / NCT00749580
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
Completed
46 enrolled
University of South Florida
Merck Sharp & Dohme LLC · collabSt. Joseph's Hospital, Florida · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
Timeline
- Start
- 2008-11
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |